ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa

Not Applicable

Completed

Conditions: HIV Infection

Interventions: Other: HIV quarterly global care

First Posted Date: 2015-12-10

Last Posted Date: 2021-04-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 885

Registration Number: NCT02626286

Locations: 🇲🇱
Clinique des Halles, ARCAD-SIDA, Bamako, Mali
🇹🇬
Espoir vie Togo, Lome, Togo
🇧🇫
Centre Oasis, Association African Solidarité (AAS), Ouagadougou, Burkina Faso

and more 1 locations

Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS

Not Applicable

Conditions: Cryptococcal Meningitis

Interventions: Drug: Antiretroviral therapy
Drug: Fluconazole

First Posted Date: 2015-12-08

Last Posted Date: 2018-03-15

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 186

Registration Number: NCT02624453

Locations: 🇨🇲
Day Hospital of the Yaounde Central Hospital, Yaounde, Central Region, Cameroon

Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study

Not Applicable

Completed

Conditions: HIV-1 Infection

Interventions: Other: Health related quality of life and social and demographic informations
Other: Neurocognitive assessment
Radiation: cerebral images sub-study

First Posted Date: 2015-10-30

Last Posted Date: 2018-01-08

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 220

Registration Number: NCT02592174

Locations: 🇫🇷
Hôpital Michallon- Service des Maladies Infectieuses, Grenoble, France
🇫🇷
Hôpital Bretonneau - Service des Maladies Infectieuses, Tours, France
🇫🇷
Centre Hospitalier de Cannes - Service de Médecine Interne Oncologie, Cannes, France

and more 3 locations

Evaluation of an Innovative Tuberculosis Diagnostic Test

Conditions: Tuberculosis
HIV

First Posted Date: 2015-10-12

Last Posted Date: 2015-10-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 300

Registration Number: NCT02573623

Locations: 🇿🇲
Department of Paediatrics and Child Health, University Teaching Hospital.UNZA-SOM, Lusaka, Zambia

Feasibility of Interventions on People Who Inject Drugs in Vietnam

Completed

Conditions: Substance Abuse
Hepatitis Virus
HIV

First Posted Date: 2015-10-12

Last Posted Date: 2018-09-18

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 603

Registration Number: NCT02573948

Locations: 🇻🇳
Hai Phong Medical University, Hai Phong, Vietnam

A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)

Not Applicable

Conditions: HIV-uninfected Children
HIV
Children Exposed to HIV

Interventions: Other: HIV-infected children initiated antiretroviral treatment within the first 7 months of life

First Posted Date: 2015-10-07

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 400

Registration Number: NCT02570334

Locations: 🇨🇲
Centre Hospitalier d'Essos, Yaounde, Cameroon
🇨🇲
Hôpital de Laquintinie, Douala, Cameroon
🇨🇲
Hôpital de la Fondation Mère-enfant Chantal Biya, Yaounde, Cameroon

Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France

Completed

Conditions: Chronic Hepatitis B
HIV Infection

First Posted Date: 2015-10-02

Last Posted Date: 2017-05-15

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 2468

Registration Number: NCT02566148

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: dolutegravir (Tivicay®) - Phase 1
Drug: lamivudine (Epivir®) - Phase 2
Drug: dolutegravir (Tivicay®) - Phase 2

First Posted Date: 2015-08-18

Last Posted Date: 2017-08-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 110

Registration Number: NCT02527096

Locations: 🇫🇷
Hôpital Bichat, Paris, France
🇫🇷
Hôpital Saint-André, Bordeaux, France
🇫🇷
Hôpital du Bocage, Dijon, France

and more 15 locations

Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa

Phase 2

Completed

Conditions: Hepatitis C
HIV Infection

Interventions: Drug: Sofosbuvir
Drug: Ribavirin
Drug: Ledipasvir

First Posted Date: 2015-04-01

Last Posted Date: 2017-12-13

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 120

Registration Number: NCT02405013

Locations: 🇨🇮
CHU de Youpougon - Service de Gastro-entéro-hépatologie, Abidjan, Côte D'Ivoire
🇨🇲
Clinique de la Cathédrale, Yaoundé, Cameroon
🇸🇳
CHU Fann, Service des Maladies Infectieuses, Dakar, Senegal

and more 1 locations

Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients

Phase 2

Completed

Conditions: HIV INFECTION

Interventions: Drug: Darunavir

First Posted Date: 2015-03-10

Last Posted Date: 2017-01-24

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 100

Registration Number: NCT02384967

Locations: 🇫🇷
Hôpital Saint Louis, Paris, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy